Finance

Lists
ORIC:NASDAQ
ORIC Pharmaceuticals Inc
$12.50
-0.95%
(-0.12) 1D
$12.50
0.00% (0.00)
After hours
Closed: Sep 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ORIC...
Open
$12.50
High
$13.00
Low
$12.31
Mkt. cap
1.30B
Avg. vol.
1.35M
Volume
0.00
52-wk high
$14.93
52-wk low
$7.23
EPS
-$1.35
Beta
1.00
Shares outstanding
103.65M
No. of employees
111
Open
$12.50
High
$13.00
Low
$12.31
Mkt. cap
1.30B
Avg. vol.
1.35M
Volume
0.00
52-wk high
$14.93
52-wk low
$7.23
EPS
-$1.35
Beta
1.00
Shares outstanding
103.65M
No. of employees
111
News stories
From web sources and news partners
About ORIC Pharmaceuticals Inc
CEO-
Employees111
Founded2014
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiteoricpharma.com
Analyst ratings
Based on 8 analysts giving stock ratings to ORIC in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ORIC in the last 3 months.
Highest
Current $12.50
$27.00 (+116.00%)
Average
$22.38 (+79.04%)
Lowest
$14.00 (+12.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$27.00
+116%
08/10/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$23.00
+84%
08/06/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$25.00
+100%
08/04/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$14.00
+12%
08/04/2026
Derek Archila
Wells Fargo
Buy
Maintained
$25.00
+100%
08/04/2026
Boris Peaker
JonesTrading
Buy
Maintained
$25.00
+100%
08/04/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$18.00
+44%
08/03/2026
Kelsey Goodwin
Piper Sandler
Buy
Reiterated
$22.00
+76%
08/04/2026
Corinne Johnson
Goldman Sachs
Buy
Reiterated
$15.00
+20%
06/02/2026
Unknown Analyst
Wedbush
Buy
Initiated
$17.00
+36%
05/05/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$15.00
+20%
05/05/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$16.00
+28%
05/05/2026
Soumit Roy
JonesTrading
Buy
Maintained
$25.00
+100%
04/06/2026
Danya Ben-Hail
JonesTrading
Buy
Reiterated
$25.00
+100%
04/01/2026
David Nierengarten
Wedbush
Buy
Maintained
$20.00
+60%
02/24/2026
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.38 / -$0.36
-4.61%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
28.77M
25.86M
31.44M
36.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.90M
8.70M
8.18M
9.00M
Operating expense
36.67M
34.55M
39.62M
45.30M
Total operating expenses
36.67M
34.55M
39.62M
45.30M
Operating income
-36.67M
-34.55M
-39.62M
-45.30M
Other non operating income
-
-
-
-
EBT including unusual items
-32.59M
-30.50M
-35.77M
-41.49M
EBT excluding unusual items
-32.59M
-30.50M
-35.77M
-41.49M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32.59M
-30.50M
-35.77M
-41.49M
Net profit margin
-
-
-
-
Earnings per share
-0.33
-0.30
-0.34
-0.38
Interest and investment income
4.08M
4.05M
3.85M
3.80M
Interest expense
-
-
-
-
Net interest expenses
4.08M
4.05M
3.85M
3.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-36.38M
-34.23M
-39.35M
-45.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps